The present study reports the LDL-Cholesterol lowering effects of Simvastatin. The LDL-Cholesterol lowering effects of generic products of Simvastatin have been compared to the original brand of Simvastatin i.e. Zocor in hypercholesterolemic subjects. The generic drugs used were of Atco Laboratories and that of Pharm evo Laboratories.
All the drugs used in the present study significantly reduced the total cholesterol; the serum triglycerides and the Low density lipoproteins cholesterol (LDL-C). High density lipoprotein (HDL); however increased significantly in all the three groups.
The group A Le. Zocor treated individuals after 90 days of drug administration showed a decrease in cholesterol from 242.18±42.15 to 166.20±31.24. The triglycerides reduced from 289.18±149.14 to 213.36±103.12. LDL-C reduced from 192.92±29.65 to 125.00±17.33; however the HDL increased from 30.83 to 36.33 after 90 days of treatment which has increased significantly.
In group B i.e. Atcol treated group after 90 days of treatment total cholesterol decreased from 242.77±46.92 on day 0 to 167.61±35.78 on day 90. The mean serum triglycerides level decreased significantly from 291.56±148.44 to 221.88±106.61±on day 90. Highly significant decrease in serum low density lipoprotein cholesterol (LDL-C) was observed which decreased from185.52±19.59 on day 0 to 123.00±12.87 on day 90. However serum high density cholesterol (HDL-C) increased from 31.80±4.98 on day 0 to 37.01±5.610n day 90.
In Limitrol treated group i.e. group C; a significant decrease in cholesterol was observed from 238.37±48.35 to 160.14±21.83 on day 90. The triglycerides reduced from 243.00±41.19 to 175.37±31.30 on day 90; similarly LDL-C reduced from 186.31±10.35 to 124.00±9.94 on day 90. However HDL-C increased from 31.14±5.44 on day 0 to 37.00±4.87 on day 90.
Subsequently, safety of statin therapy was also observed in this study. As for as the safety is concerned; the results in our study show that, Zocor, Atcol; as well as Limitrol caused no serious adverse effects. In all 7 patients from group A; 9 patients from group B; and 11 patients from group C showed the side effects. The side effects were not severe to discontinue the treatment. Reassurance and symptomatic treatment was sufficient to continue the therapy.
Out of 264 patients in this study; 8 patients from group A were lost during the study period and similarly other 08 patients were lost from group B and further 07 patients were lost during the study period from group C. In all 23 patients were dropped from the study.